Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?